Cytosorbents Has Completed Enrollment In The Pivotal Safe And Timely Antithrombotic Removal – Ticagrelor Trial, Evaluating The Ability Of DrugSorb-ATR To Reduce Perioperative Bleeding In Patients Undergoing Cardiothoracic Surgery On Ticagrelor
Portfolio Pulse from Benzinga Newsdesk
Cytosorbents has completed enrollment in the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor trial. The trial is evaluating the ability of DrugSorb-ATR to reduce perioperative bleeding in patients undergoing cardiothoracic surgery on Ticagrelor.
July 07, 2023 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cytosorbents has completed enrollment for a pivotal trial of DrugSorb-ATR. The trial's success could potentially boost the company's reputation and stock value.
The completion of enrollment for a pivotal trial is a significant milestone for any healthcare company. If the trial results are positive, it could lead to regulatory approval and commercialization of the product, potentially increasing the company's revenues and boosting its stock value.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100